Focused Investors LLC Decreases Holdings in Johnson & Johnson $JNJ

Key Points

• Focused Investors LLC trimmed its Johnson & Johnson stake by 2.6% in Q4, selling 25,150 shares and ending the period with 959,600 shares (~$198.59M), which is about 6.3% of the fund and its third-largest holding.
• J&J beat Q1 estimates with $2.70 EPS and $24.06B revenue, set FY2026 guidance of $11.45–$11.65 EPS, and carries an analyst consensus of "Moderate Buy" with an average target of $252.48.
• Dividend and insider activity: the company raised its quarterly dividend to $1.34 (annual $5.36, ~2.3% yield), while insiders have sold about 30,142 shares (~$7.36M) over the past 90 days.

Focused Investors LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.6% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 959,600 shares of the company's stock after selling 25,150 shares during the quarter. Johnson & Johnson accounts for about 6.3% of Focused Investors LLC's investment portfolio, making the stock its 3rd largest position. Focused Investors LLC's holdings in Johnson & Johnson were worth $198,589,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Wellington Management Group LLP increased its stake in Johnson & Johnson by 3.8% in the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock worth $4,789,914,000 after acquiring an additional 956,239 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Johnson & Johnson by 3.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company's stock valued at $4,568,313,000 after purchasing an additional 835,146 shares during the last quarter. Legal & General Group Plc increased its position in shares of Johnson & Johnson by 2.8% during the 3rd quarter. Legal & General Group Plc now owns 19,450,064 shares of the company's stock valued at $3,606,431,000 after purchasing an additional 532,790 shares during the last quarter. Amundi increased its position in shares of Johnson & Johnson by 19.3% during the 3rd quarter. Amundi now owns 13,354,936 shares of the company's stock valued at $2,512,719,000 after purchasing an additional 2,163,838 shares during the last quarter. Finally, Raymond James Financial Inc. increased its position in shares of Johnson & Johnson by 7.3% during the 3rd quarter. Raymond James Financial Inc. now owns 10,137,651 shares of the company's stock valued at $1,879,718,000 after purchasing an additional 690,887 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,251,310.02. This represents a 4.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 over the last 90 days. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 2.0%

Shares of JNJ stock opened at $230.67 on Friday. The stock has a market capitalization of $555.60 billion, a PE ratio of 26.67, a P/E/G ratio of 2.21 and a beta of 0.34. Johnson & Johnson has a 1-year low of $146.12 and a 1-year high of $251.71. The business has a 50-day moving average of $240.50 and a 200 day moving average of $218.19. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. The company had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.75% and a net margin of 21.83%.Johnson & Johnson's quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.3%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's dividend payout ratio (DPR) is currently 60.12%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Long‑term Phase 3 and open‑label extension data for IMAAVY (nipocalimab) showed sustained disease control and safety through ~120 weeks in generalized myasthenia gravis; J&J also started the first industry head‑to‑head FcRn study — these clinical wins strengthen JNJ’s immunology franchise and future revenue potential. IMAAVY press release
• Positive Sentiment: New AI and EP (electrophysiology) product updates — including the CARTOSOUND SONATA AI module and expanded VARIPULSE data — add visible growth optionality in cardiac devices and services, helping justify premium valuation for the MedTech segment. AI Cardiac Tools article
• Positive Sentiment: Strategic commercial collaboration with Viz.ai to deploy AI subdural hemorrhage detection across U.S. hospitals broadens J&J’s neurovascular offering and supports recurring software/solution revenue opportunities. Viz.ai collaboration
• Positive Sentiment: CE Mark approval for the new ETHICON 4000 surgical stapler is a commercial milestone that supports device sales growth in Europe and enhances the surgical portfolio’s near‑term revenue trajectory. ETHICON 4000 CE Mark
• Positive Sentiment: Technical and sentiment catalysts: Seeking Alpha notes JNJ snapped a six‑session losing streak, and high‑profile endorsements / analyst attention (including Jim Cramer buys and a Guggenheim mention) are drawing retail and institutional interest. Seeking Alpha: snap losses Jim Cramer mention Guggenheim analyst note
• Neutral Sentiment: Coverage pieces highlight JNJ as a defensive/dividend and counter‑cyclical pick, which can attract income‑oriented buyers but is a longer‑term narrative rather than an immediate catalyst. Dividend stocks article Counter cyclical article

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. HSBC increased their price objective on Johnson & Johnson from $265.00 to $280.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. Rothschild & Co Redburn increased their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the company a "neutral" rating in a research report on Thursday, February 19th. Freedom Capital lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 16th. Argus increased their price objective on Johnson & Johnson from $240.00 to $275.00 and gave the company a "buy" rating in a research report on Thursday, April 16th. Finally, TD Cowen initiated coverage on Johnson & Johnson in a research report on Wednesday, April 8th. They set a "buy" rating and a $250.00 price objective on the stock. Eighteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $252.48.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.